EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis

Di Kang, Jing Li, Yangyang Li, Jingquan Xu, Jianlei Yang, Zili Zhang iD

PLOS One · 25.04.2025 · 20 (4) · e0320783

DOI: 10.1371/journal.pone.0320783 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS One, online erschienen am 25.04.2025. Verfasst von Di Kang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Tianjin Third Central Hospital, The Third Central Clinical College of Tianjin Medical University, Tianjin Key Laborato…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prognostic significance of KRAS and BRAF mutations is well-established in metastatic colorectal cancer (CRC) but remains uncertain in early-stage tumors. This study retrospectively analyzed 47 stage II/III CRC patients undergoing curative surgery to assess the association of mutations in KRAS , NRAS , BRAF , and PIK3CA with overall survival (OS) and disease-free survival (DFS). Additionally, a meta-analysis was conducted to validate the prognostic relevance of these gene mutations. We included post hoc analyses of phase III randomized controlled trials (RCTs) in stage II/III patients receiving adjuvant therapy after curative resection in the meta-analysis. Pooled hazard ratio (HR) and 95% confidence interval (CI) was calculated using a random-effect model in the overall population, stratified subgroups adjusted for microsatellite instability (MSI) status, and within MSI-high (MSI-H) and microsatellite-stable (MSS) populations. In the retrospective cohort, mutations in KRAS , NRAS , BRAF , and PIK3CA were identified in 29.8%, 4.3%, 8.5%, and 14.9% of patients, respectively. No significant association between individual genes and survival was observed. However, in MSS patients, concurrent mutations were significantly associated with shorter OS and DFS (log-rank test, P < 0.05). The meta-analysis incorporated 13 eligible studies, including 15,034 patients. Pooled analyses revealed that KRAS and BRAF mutations were significantly linked to poor OS ( KRAS : HR = 1.25, 95%CI: 1.06-1.47, P = 0.008; BRAF : HR = 1.43, 95%CI: 1.26-1.63, P < 0.001) and DFS ( KRAS : HR = 1.36, 95%CI: 1.21-1.53, P < 0.001; BRAF : HR = 1.21, 95%CI: 1.02-1.44, P = 0.032). The prognostic impact of BRAF mutation increased with MSI adjustment compared those without MSI adjustment. In MSS tumors, KRAS -mutant patients demonstrated significantly shorter DFS (HR = 1.63, 95%CI: 1.25-2.13, P < 0.001), while BRAF -mutant patients exhibited reduced OS (HR = 1.53, 95%CI: 1.24-1.89, P < 0.001) and DFS (HR = 1.72, 95%CI: 1.20-2.46, P = 0.003) compared to wildtype patients. Conversely, no significant survival differences were found between mutant and wildtype patients in the MSI-H population. Although PIK3CA mutation was nominally associated with OS (HR = 0.86, 95%CI: 0.75-1.00, P = 0.046), the pooled result lacked robustness. In conclusion, KRAS and BRAF mutations had a negative prognostic impact on MSS stage II/III CRC patients receiving adjuvant therapy following curative resection. These patients may benefit from more effective adjuvant treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafColorectal NeoplasmsMutationProto-Oncogene Proteins p21(ras)GTP PhosphohydrolasesMembrane ProteinsPhosphatidylinositol 3-KinasesHumansClass I Phosphatidylinositol 3-KinasesRetrospective StudiesFemaleMalePrognosisMiddle AgedAgedMicrosatellite InstabilityNeoplasm StagingAdultDisease-Free Survival

Substanzen

Proto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesPIK3CA protein, humanNRAS protein, humanProto-Oncogene Proteins p21(ras)BRAF protein, humanGTP PhosphohydrolasesMembrane ProteinsKRAS protein, humanPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of General Surgery, Tianjin Third Central Hospital, The Third Central Clinical College of Tianjin Medical University, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Ce…

ORCID-Profile: Zili Zhang

Zitieren

APA

Kang, D., Li, J., Li, Y., Xu, J., Yang, J., & Zhang, Z. (2025). Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis. PLOS One, 20(4), e0320783. https://doi.org/10.1371/journal.pone.0320783

Vancouver

Kang D, Li J, Li Y, Xu J, Yang J, Zhang Z. Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis. PLOS One. 2025;20(4):e0320783. doi:10.1371/journal.pone.0320783

BibTeX
@article{Kang2025,
  author = {Kang, Di and Li, Jing and Li, Yangyang and Xu, Jingquan and Yang, Jianlei and Zhang, Zili},
  title = {Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {4},
  pages = {e0320783},
  doi = {10.1371/journal.pone.0320783}
}
Kostenlos starten →